Dr. Michael H. May Ph.D. serves as Independent Director of the Company. Dr. May is President and Chief Executive Officer of CCRM Enterprises and the Center for Commercialization of Regenerative Medicine or CCRM, a public-private consortium founded under Canada’s Centres of Excellence for Commercialization and Research Program to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine. Dr. May co-founded Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity, and served as President and Chief Executive Officer of Rimon from 2000 to 2006, and President and Chief Operating Officer from 2006 to 2010. Dr. May serves on a number of boards of directors and advisory committees in the field of stem cell research and regenerative medicine, including at the International Society for Cell Therapy (ISCT) and the Alliance for Regenerative Medicine (ARM). Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
Michael May is 51, he's been the Independent Director of AgeX Therapeutics Inc since 2019. There are 7 older and 4 younger executives at AgeX Therapeutics Inc. The oldest executive at AgeX Therapeutics Inc is Judith Segall, 68, who is the Sec..
Michael's mailing address filed with the SEC is C/O AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA, CA, 94501.
Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West und Judith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
AgeX Therapeutics Inc executives and other stock owners filed with the SEC include: